123 related articles for article (PubMed ID: 1474818)
1. [Comparative evaluation of the effectiveness of mono- and polychemotherapy programs in patients with multiple myeloma].
Abdulkadyrov KM; Bessmel'tsev SS
Klin Med (Mosk); 1992; 70(9-10):57-60. PubMed ID: 1474818
[No Abstract] [Full Text] [Related]
2. Bortezomib data show improved survival in patients with relapsed multiple myeloma.
Oncology (Williston Park); 2004 Aug; 18(9):1199, 1201. PubMed ID: 15471202
[No Abstract] [Full Text] [Related]
3. [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].
Wu KL; Schaafsma MR; Lokhorst HM; Wijermans PW; van der Holt B; Sonneveld P
Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1445-8. PubMed ID: 12190011
[TBL] [Abstract][Full Text] [Related]
4. [Polychemotherapy versus melphalan-prednisone in multiple myeloma].
Leoni P; Salvi A; Brianzoni MF; Centurioni R; Montillo M; Olivieri A
G Clin Med; 1986 Dec; 67(5-6):291-6. PubMed ID: 3609590
[No Abstract] [Full Text] [Related]
5. Polychemotherapy (COMP) treatment in myeloma patients. A preliminary report.
Izzi T; Polchi P; Moretti L; Lucarelli G
Haematologica; 1983; 68(3):381-91. PubMed ID: 6411532
[No Abstract] [Full Text] [Related]
6. Treatment of multiple myeloma and arterial thrombosis.
Raven W; Berghout A; van Houten A; Leebeek FW
Ann Hematol; 2010 Apr; 89(4):419-20. PubMed ID: 19688212
[No Abstract] [Full Text] [Related]
7. Bortezomib therapy following first relapse.
Orlowski RZ;
Oncology (Williston Park); 2005 Jan; 19(1):23-6. PubMed ID: 15743149
[No Abstract] [Full Text] [Related]
8. Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study.
Offidani M; Marconi M; Corvatta L; Olivieri A; Catarini M; Leoni P
Haematologica; 2003 Dec; 88(12):1432-3. PubMed ID: 14688003
[No Abstract] [Full Text] [Related]
9. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients.
Morgan GJ; Schey SA; Wu P; Srikanth M; Phekoo KJ; Jenner M; Davies FE
Br J Haematol; 2007 May; 137(3):268-9. PubMed ID: 17408469
[No Abstract] [Full Text] [Related]
10. [The efficacy of polychemotherapy programs in treating multiple myeloma patients].
Bessmel'tsev SS; Abdulkadyrov KM; Rukavitsyn OA
Ter Arkh; 1998; 70(7):46-9. PubMed ID: 9742636
[TBL] [Abstract][Full Text] [Related]
11. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
Jagannath S; Barlogie B; Berenson JR; Siegel DS; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Esseltine DL; Anderson KC
Br J Haematol; 2008 Nov; 143(4):537-40. PubMed ID: 18783399
[TBL] [Abstract][Full Text] [Related]
12. [Multiple myeloma].
Kanoh T
Rinsho Ketsueki; 1989 Aug; 30(8):1212-5. PubMed ID: 2601036
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma.
Riccardi A; Mora O; Tinelli C; Valentini D; Brugnatelli S; Spanedda R; De Paoli A; Barbarano L; Di Stasi M; Giordano M; Delfini C; Nicoletti G; Bergonzi C; Rinaldi E; Piccinini L; Ascari E
Br J Cancer; 2000 Apr; 82(7):1254-60. PubMed ID: 10755397
[TBL] [Abstract][Full Text] [Related]
14. Reply. Kastritis E. et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone containing regimes and the impact of novel agents. Haematologica 2007; 92:546-9.
Bergner R; Hoffmann M; Uppenkamp M
Haematologica; 2008 Jan; 93(1):e18-9. PubMed ID: 18166771
[No Abstract] [Full Text] [Related]
15. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
16. [Multiple myeloma: therapeutic response to 2 modalities of chemotherapy].
Lira P; Walker B; Grebe G
Rev Med Chil; 1986 May; 114(5):436-40. PubMed ID: 3589221
[No Abstract] [Full Text] [Related]
17. [Characteristics of drug resistance of tumor plasmocytes in vitro in patients with multiple myeloma differently responsive to chemotherapy].
Golenkov AK; Trifonova EV; Kataeva EV; Kil'diushevskiĭ AV; Lutskaia TD; Zariad'eva EA; Nazarova IN; Lukashina MN; Zabotina TN; Mikhaĭlova IN; Inshakov AN; Logacheva NP; Baryshnikov AIu
Ter Arkh; 2000; 72(8):38-41. PubMed ID: 11019426
[TBL] [Abstract][Full Text] [Related]
18. [Clinical and laboratory analysis of the cases of multiple myeloma with over 5-year survival time from the beginning of the antineoplastic treatment].
Kraj M; Rostkowska J; Sokołowska U; Maj S
Acta Haematol Pol; 1991; 22(1):42-7. PubMed ID: 1823966
[TBL] [Abstract][Full Text] [Related]
19. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma.
Wang M; Weber DM; Delasalle K; Alexanian R
Am J Hematol; 2005 Jul; 79(3):194-7. PubMed ID: 15981221
[TBL] [Abstract][Full Text] [Related]
20. [Combination chemotherapy of multiple myeloma].
Uzuka Y; Saito Y; Ito T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1481-7. PubMed ID: 2389944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
